SE9200951D0 - Pharmaceutical composition containing a defined lipid system - Google Patents

Pharmaceutical composition containing a defined lipid system

Info

Publication number
SE9200951D0
SE9200951D0 SE9200951A SE9200951A SE9200951D0 SE 9200951 D0 SE9200951 D0 SE 9200951D0 SE 9200951 A SE9200951 A SE 9200951A SE 9200951 A SE9200951 A SE 9200951A SE 9200951 D0 SE9200951 D0 SE 9200951D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical composition
composition containing
lipid system
lipid
defined lipid
Prior art date
Application number
SE9200951A
Other languages
English (en)
Swedish (sv)
Inventor
M Einarsson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9200951A priority Critical patent/SE9200951D0/xx
Publication of SE9200951D0 publication Critical patent/SE9200951D0/xx
Priority to ZA931470A priority patent/ZA931470B/xx
Priority to IL10501793A priority patent/IL105017A/en
Priority to HU9303357A priority patent/HU219240B/hu
Priority to PCT/SE1993/000258 priority patent/WO1993019737A1/en
Priority to DE69318503T priority patent/DE69318503T2/de
Priority to JP51736193A priority patent/JP3577312B2/ja
Priority to AU39124/93A priority patent/AU3912493A/en
Priority to AT93908233T priority patent/ATE165971T1/de
Priority to MX9301716A priority patent/MX9301716A/es
Priority to RU93058379A priority patent/RU2128505C1/ru
Priority to ES93908233T priority patent/ES2116447T3/es
Priority to KR1019930703632A priority patent/KR100243921B1/ko
Priority to CA002102494A priority patent/CA2102494C/en
Priority to PL93301465A priority patent/PL172896B1/pl
Priority to DK93908233T priority patent/DK0591492T3/da
Priority to SK1322-93A priority patent/SK280494B6/sk
Priority to EP93908233A priority patent/EP0591492B1/en
Priority to NZ251488A priority patent/NZ251488A/en
Priority to CZ932477A priority patent/CZ285672B6/cs
Priority to FI935273A priority patent/FI110842B/fi
Priority to NO934284A priority patent/NO305537B1/no
Priority to US08/497,381 priority patent/US5626869A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE9200951A 1992-03-27 1992-03-27 Pharmaceutical composition containing a defined lipid system SE9200951D0 (sv)

Priority Applications (23)

Application Number Priority Date Filing Date Title
SE9200951A SE9200951D0 (sv) 1992-03-27 1992-03-27 Pharmaceutical composition containing a defined lipid system
ZA931470A ZA931470B (en) 1992-03-27 1993-03-02 A pharmaceutical composition containing a defined lipid system.
IL10501793A IL105017A (en) 1992-03-27 1993-03-11 Pharmaceutical composition containing a defined two component lipid system
CZ932477A CZ285672B6 (cs) 1992-03-27 1993-03-26 Farmaceutický prostředek obsahující definovaný lipidový systém
RU93058379A RU2128505C1 (ru) 1992-03-27 1993-03-26 Фармацевтическая композиция с липидной системой
KR1019930703632A KR100243921B1 (ko) 1992-03-27 1993-03-26 규정된 지질계를 함유하는 제약조성물
DE69318503T DE69318503T2 (de) 1992-03-27 1993-03-26 Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
JP51736193A JP3577312B2 (ja) 1992-03-27 1993-03-26 定義された脂質系を含有する薬剤組成物
AU39124/93A AU3912493A (en) 1992-03-27 1993-03-26 A pharmaceutical composition containing a defined lipid system
AT93908233T ATE165971T1 (de) 1992-03-27 1993-03-26 Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
MX9301716A MX9301716A (es) 1992-03-27 1993-03-26 Una composicion farmaceutica que tiene un sistema definido de lipidos.
HU9303357A HU219240B (en) 1992-03-27 1993-03-26 A pharmaceutical composition containing lipid system and heparine, and process for its production
ES93908233T ES2116447T3 (es) 1992-03-27 1993-03-26 Una composicion farmaceutica que contiene un sistema definido de lipidos.
PCT/SE1993/000258 WO1993019737A1 (en) 1992-03-27 1993-03-26 A pharmaceutical composition containing a defined lipid system
CA002102494A CA2102494C (en) 1992-03-27 1993-03-26 A pharmaceutical composition containing a defined lipid system
PL93301465A PL172896B1 (pl) 1992-03-27 1993-03-26 Kompozycja farmaceutyczna zawierajaca scisle okreslony system lipidowy i sposób wytwarzania kompozycji farmaceutycznej zawierajacej scisle okreslony system lipidowy PL PL PL
DK93908233T DK0591492T3 (da) 1992-03-27 1993-03-26 Farmaceutisk præparat indeholdende et defineret lipidsystem
SK1322-93A SK280494B6 (sk) 1992-03-27 1993-03-26 Farmaceutický prostriedok obsahujúci systém lipido
EP93908233A EP0591492B1 (en) 1992-03-27 1993-03-26 A pharmaceutical composition containing a defined lipid system
NZ251488A NZ251488A (en) 1992-03-27 1993-03-26 Pharmaceutical lipid system: two lipids (one polar, one non-polar) and a heparin derivative
NO934284A NO305537B1 (no) 1992-03-27 1993-11-26 Farmas°ytisk preparat inneholdene et definert lipidsystem, og anvendelse av lipidsystemet
FI935273A FI110842B (fi) 1992-03-27 1993-11-26 Menetelmä määritellyn lipidijärjestelmän sisältävän farmaseuttisen koostumuksen valmistamiseksi
US08/497,381 US5626869A (en) 1992-03-27 1995-06-29 Pharmaceutical composition containing a defined lipid system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9200951A SE9200951D0 (sv) 1992-03-27 1992-03-27 Pharmaceutical composition containing a defined lipid system

Publications (1)

Publication Number Publication Date
SE9200951D0 true SE9200951D0 (sv) 1992-03-27

Family

ID=20385757

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9200951A SE9200951D0 (sv) 1992-03-27 1992-03-27 Pharmaceutical composition containing a defined lipid system

Country Status (23)

Country Link
US (1) US5626869A (cs)
EP (1) EP0591492B1 (cs)
JP (1) JP3577312B2 (cs)
KR (1) KR100243921B1 (cs)
AT (1) ATE165971T1 (cs)
AU (1) AU3912493A (cs)
CA (1) CA2102494C (cs)
CZ (1) CZ285672B6 (cs)
DE (1) DE69318503T2 (cs)
DK (1) DK0591492T3 (cs)
ES (1) ES2116447T3 (cs)
FI (1) FI110842B (cs)
HU (1) HU219240B (cs)
IL (1) IL105017A (cs)
MX (1) MX9301716A (cs)
NO (1) NO305537B1 (cs)
NZ (1) NZ251488A (cs)
PL (1) PL172896B1 (cs)
RU (1) RU2128505C1 (cs)
SE (1) SE9200951D0 (cs)
SK (1) SK280494B6 (cs)
WO (1) WO1993019737A1 (cs)
ZA (1) ZA931470B (cs)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
KR100314496B1 (ko) 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
JP4198318B2 (ja) 1998-08-19 2008-12-17 ヤーゴテック アクチェンゲゼルシャフト プロポフォールの注射可能水性分散物
CN1320880C (zh) 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
DE10038203A1 (de) 1999-08-06 2001-05-03 Max Delbrueck Centrum Implantierbares Wirkstoffdepot
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
FR2803202B1 (fr) * 2000-01-03 2004-04-16 Capsulis Compositions pharmaceutiques destinees a une adminstration par voie orale
SE0000730D0 (sv) * 2000-03-06 2000-03-06 Scotia Holdings Plc Lipid carrier
US6761901B1 (en) * 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials
US9308220B2 (en) * 2001-12-11 2016-04-12 Cosmo Technologies Limited Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
SE0201922D0 (sv) * 2002-06-20 2002-06-20 Ltp Lipid Technologies Provide Koagulationshindrande komposition (Anticoagulant Composition)
US6702850B1 (en) * 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2005094785A2 (en) * 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
US20100021538A1 (en) * 2008-02-29 2010-01-28 Youngro Byun Pharmaceutical compositions containing heparin derivatives
MX2011004859A (es) 2008-11-07 2011-08-03 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
PL3338765T3 (pl) 2009-12-01 2019-06-28 Translate Bio, Inc. Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
EP2512448B1 (en) 2009-12-18 2016-07-06 Endotis Pharma Pharmaceutical oral dosage form containing a synthetic oligosaccharide
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
EP3919505B1 (en) 2013-01-16 2023-08-30 Emory University Uses of cas9-nucleic acid complexes
US9303263B2 (en) 2013-03-01 2016-04-05 Vivonics, Inc. Aptamers that bind CD271
ES2981185T3 (es) 2013-03-14 2024-10-07 Translate Bio Inc Métodos para la purificación de ARN mensajero
EP2968586B1 (en) 2013-03-14 2018-07-25 Translate Bio, Inc. Cftr mrna compositions and related methods and uses
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
WO2015061467A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
JP6571679B2 (ja) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
KR20170005494A (ko) 2014-05-30 2017-01-13 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 잠복 바이러스 감염에 대한 치료제를 전달하는 조성물 및 방법
CA2952824C (en) 2014-06-24 2023-02-21 Shire Human Genetic Therapies, Inc. Stereochemically enriched compositions for delivery of nucleic acids
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
CA3000155A1 (en) 2015-05-29 2016-12-08 Agenovir Corporation Compositions and methods for cell targeted hpv treatment
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
CN118421617A (zh) 2018-08-24 2024-08-02 川斯勒佰尔公司 用于纯化信使rna的方法
EP3883592A1 (en) 2018-11-21 2021-09-29 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
WO2021055609A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
WO2021081469A2 (en) 2019-10-25 2021-04-29 The Johns Hopkins University Light-inducible crispr/cas9 system for genome editing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8219012A0 (it) * 1982-01-06 1982-01-06 Ausonia Farma Srl Metodo per la somministrazione orale di sostanze sotto forma di liposomi, e relative formulazioni farmaceutiche.
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
JPS607934A (ja) * 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
EP0158441B2 (en) * 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposome-forming composition
GB8613811D0 (en) * 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
IE59067B1 (en) * 1985-04-02 1993-12-15 Yesair David W Composition for delivery of orally administered drugs and other substances
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
SE8603812D0 (sv) * 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
DE3852409T2 (de) * 1987-01-27 1995-04-20 Vestar Inc Aus Phospholipiden bestehende Darreichungsform für wasserunlösliche Wirksubstanzen.
SE9003100D0 (sv) * 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system

Also Published As

Publication number Publication date
SK132293A3 (en) 1994-07-06
NO934284D0 (no) 1993-11-26
DE69318503D1 (de) 1998-06-18
CA2102494A1 (en) 1993-09-28
ATE165971T1 (de) 1998-05-15
DE69318503T2 (de) 1998-11-05
NZ251488A (en) 1996-03-26
DK0591492T3 (da) 1999-02-15
JP3577312B2 (ja) 2004-10-13
KR100243921B1 (ko) 2000-03-02
HU219240B (en) 2001-03-28
ES2116447T3 (es) 1998-07-16
WO1993019737A1 (en) 1993-10-14
CZ247793A3 (en) 1994-07-13
US5626869A (en) 1997-05-06
NO305537B1 (no) 1999-06-21
CA2102494C (en) 2008-03-18
ZA931470B (en) 1993-09-23
HUT70405A (en) 1995-10-30
MX9301716A (es) 1994-01-31
JPH06508155A (ja) 1994-09-14
SK280494B6 (sk) 2000-03-13
HU9303357D0 (en) 1994-03-28
IL105017A0 (en) 1993-07-08
NO934284L (no) 1993-11-26
FI935273L (fi) 1993-11-26
EP0591492B1 (en) 1998-05-13
FI935273A0 (fi) 1993-11-26
IL105017A (en) 1999-12-22
RU2128505C1 (ru) 1999-04-10
PL172896B1 (pl) 1997-12-31
AU3912493A (en) 1993-11-08
CZ285672B6 (cs) 1999-10-13
FI110842B (fi) 2003-04-15
EP0591492A1 (en) 1994-04-13

Similar Documents

Publication Publication Date Title
DK0591492T3 (da) Farmaceutisk præparat indeholdende et defineret lipidsystem
RU93058379A (ru) Фармацевтическая композиция, содержащая определенную липидную систему, способ получения композиции и ее применение
FI970825A7 (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyö tyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
FI971776A7 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
ATE356608T1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
ATE212351T1 (de) Androsten-derivate
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
TR200003666T2 (tr) Akut bir astım vakasının önlenmesi , tedavisi için formoterol
ES8801785A1 (es) Un procedimiento para la preparacion de nuevas azetidinonas sustituidas.
DE69521693D1 (de) Taxanderivate enthaltende arzneizubereitungen
IT1212778B (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
MA22343A1 (fr) Compositions type massepain, contenant du psyllium
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
SE9403137D0 (sv) Derivatives of carbohydrates and compositions containing them
LT96093A (en) The active ingredient of pharmaceutical composition for treating aphtae and stomatitis
MA26447A1 (fr) Analogues peptidiques de la lh-rh, leurs utilisations et compositions pharmaceutiques en contenant
ES8703872A1 (es) Procedimiento para preparar derivados de isoquinolina.
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
KR960021043A (ko) 스코폴레틴을 포함하는 b형 간염 치료제
ITMI920214A1 (it) Composizioni farmaceutiche stabili per la somministrazione orale di calcitonina